Related Experiment Video
Updated: Jul 30, 2026
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Identification of amyloid-beta binding sites using an antisense peptide approach
N G Milton1, N P Mayor, J Rawlinson
1Department of Molecular Pathology and Clinical Biochemistry, Royal Free and University College Medical School, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.
Researchers identified specific amyloid-beta (A beta) binding domains on catalase and ERAB enzymes using antisense peptide methodology. This approach helps pinpoint interactions for Alzheimer's disease (AD) therapeutic targets.
Area of Science:
- Biochemistry
- Neuroscience
- Molecular Biology
Background:
- Amyloid-beta (A beta) peptide is central to Alzheimer's disease (AD) pathology.
- A beta peptide fragments inhibit key enzymes like catalase and endoplasmic reticulum A beta binding dehydrogenase (ERAB).
Purpose of the Study:
- To identify specific domains of catalase and ERAB that interact with A beta.
- To explore the potential of antisense peptide methodology in identifying A beta-protein interactions for AD drug discovery.
Main Methods:
- Utilized antisense peptide methodology to probe A beta-enzyme interactions.
- Synthesized peptides corresponding to identified enzyme regions for binding assays.
Main Results:
- Identified specific A beta-binding domains within catalase and ERAB.
- Synthetic peptides corresponding to these domains demonstrated specific binding to A beta.
- These peptides effectively prevented A beta-induced cytotoxicity.
Conclusions:
- Antisense peptide methodology successfully identified A beta recognition sequences in target enzymes.
- This method offers a promising approach for discovering novel A beta protein interactions.
- Findings pave the way for identifying new therapeutic targets for Alzheimer's disease.
More Related Videos
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018